Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial

BACKGROUND: Thyroid cancer is the most common endocrine malignancy. Some advanced disease is, or becomes, resistant to radioactive iodine therapy (refractory disease); this holds poor prognosis of 10% 10-year overall survival. Whilst Sorafenib and Lenvatinib are now licenced for the treatment of pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Sarah R., Hall, Andrew, Buckley, Hannah L., Flanagan, Louise, Gonzalez de Castro, David, Farnell, Kate, Moss, Laura, Gregory, Rebecca, Newbold, Kate, Du, Yong, Flux, Glenn, Wadsley, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567392/
https://www.ncbi.nlm.nih.gov/pubmed/31200667
http://dx.doi.org/10.1186/s12885-019-5541-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567392/
https://www.ncbi.nlm.nih.gov/pubmed/31200667
http://dx.doi.org/10.1186/s12885-019-5541-4

Ejemplares similares